Rawat, M., Padalino, G., Adika, E., Okombo, J., Yeo, T., Brancale, A., Fidock, D. A., Hoffmann, K. F., & Lee, M. C. S. (2025). Quinoxaline-based anti-schistosomal compounds have potent anti-plasmodial activity. PLOS Pathogens, 21(2), e1012216. https://doi.org/10.1371/journal.ppat.1012216

Xie, S. C., Tai, C.-W., Morton, C. J., Ma, L., Huang, S.-C., Wittlin, S., Du, Y., Hu, Y., Dogovski, C., Salimimarand, M., Griffin, R., England, D., de la Cruz, E., Deni, I., Yeo, T., Burkhard, A. Y., Striepen, J., Schindler, K. A., Crespo, B., … Tilley, L. (2024). A potent and selective reaction hijacking inhibitor of Plasmodium falciparum tyrosine tRNA synthetase exhibits single dose oral efficacy in vivo. PLOS Pathogens, 20(12), e1012429. https://doi.org/10.1371/journal.ppat.1012429

Gomez-Gonzalez, P.-J., Gupta, A., Drought, L. G., Patel, A., Okombo, J., van der Watt, M., Walker-Gray, R., Schindler, K. A., Burkhard, A. Y., Yeo, T., Narwal, S. K., Bloxham, T. S., Flueck, C., Walker, E. M., Rey, J. A., Fairhurst, K. J., Reader, J., Park, H., Pollard, H. G., … Baker, D. A. (2024). Inhibitors of malaria parasite cyclic nucleotide phosphodiesterases block asexual blood-stage development and mosquito transmission. Science Advances, 10(49). https://doi.org/10.1126/sciadv.adq1383

Bestgen, B., Jones, S., Thathy, V., Kuemmerle, A., Barcelo, C., Haouala, A., Gossen, D., Marx, M. W., Di Resta, I., Szramowska, M., Webster, R. A., Llewellyn, S., Ritacco, D. A., Yeo, T., Leroy, D., Barber, B. E., Fidock, D. A., Griffin, P., Lickliter, J., & Chalon, S. (2024). Safety, tolerability, pharmacokinetics, and antimalarial activity of MMV533: a phase 1a first-in-human, randomised, ascending dose and food effect study, and a phase 1b Plasmodium falciparum volunteer infection study. The Lancet Infectious Diseases. https://doi.org/10.1016/s1473-3099(24)00664-9

Luth, M. R., Godinez-Macias, K. P., Chen, D., Okombo, J., Thathy, V., Cheng, X., Daggupati, S., Davies, H., Dhingra, S. K., Economy, J. M., Edgar, R. C. S., Gomez-Lorenzo, M. G., Istvan, E. S., Jado, J. C., LaMonte, G. M., Melillo, B., Mok, S., Narwal, S. K., Ndiaye, T., … Winzeler, E. A. (2024). Systematic in vitro evolution in Plasmodium falciparum reveals key determinants of drug resistance. Science, 386(6725). https://doi.org/10.1126/science.adk9893

Ferreira, L. T., Cassiano, G. C., Alvarez, L. C. S., Okombo, J., Calit, J., Fontinha, D., Gil-Iturbe, E., Coyle, R., Andrade, C. H., Sunnerhagen, P., Bargieri, D. Y., Prudêncio, M., Quick, M., Cravo, P. V., Lee, M. C. S., Fidock, D. A., & Costa, F. T. M. (2024). A novel 4-aminoquinoline chemotype with multistage antimalarial activity and lack of cross-resistance with PfCRT and PfMDR1 mutants. PLOS Pathogens, 20(10), e1012627. https://doi.org/10.1371/journal.ppat.1012627

Brettell, S. B., Janha, O., Begen, A., Cann, G., Sharma, S., Olaniyan, N., Yelland, T., Hole, A. J., Alam, B., Mayville, E., Gillespie, R., Capper, M., Fidock, D. A., Milligan, G., Clarke, D. J., Tobin, A. B., & Jamieson, A. G. (2024). Targeting PfCLK3 with Covalent Inhibitors: A Novel Strategy for Malaria Treatment. Journal of Medicinal Chemistry, 67(21), 18895–18910. https://doi.org/10.1021/acs.jmedchem.4c01300

Awalt, J. K., Su, W., Nguyen, W., Loi, K., Jarman, K. E., Penington, J. S., Ramesh, S., Fairhurst, K. J., Yeo, T., Park, H., Uhlemann, A.-C., Chandra Maity, B., De, N., Mukherjee, P., Chakraborty, A., Churchyard, A., Famodimu, M. T., Delves, M. J., Baum, J., … Sleebs, B. E. (2024). Exploration and characterization of the antimalarial activity of cyclopropyl carboxamides that target the mitochondrial protein, cytochrome b. European Journal of Medicinal Chemistry, 280, 116921. https://doi.org/10.1016/j.ejmech.2024.116921

Calic, P. P. S., Ashton, T. D., Mansouri, M., Loi, K., Jarman, K. E., Qiu, D., Lehane, A. M., Roy, S., Rao, G. P., Maity, B., Wittlin, S., Crespo, B., Gamo, F.-J., Deni, I., Fidock, D. A., Chowdury, M., de Koning-Ward, T. F., Cowman, A. F., Jackson, P. F., … Sleebs, B. E. (2024). Optimization of pyrazolopyridine 4-carboxamides with potent antimalarial activity for which resistance is associated with the P. falciparum transporter ABCI3. European Journal of Medicinal Chemistry, 276, 116677. https://doi.org/10.1016/j.ejmech.2024.116677

Commons, R. J., Rajasekhar, M., Allen, E. N., Yilma, D., Chotsiri, P., Abreha, T., Adam, I., Awab, G. R., Barber, B. E., Brasil, L. W., Chu, C. S., Cui, L., Edler, P., Gomes, M. do S. M., Gonzalez‑Ceron, L., Grigg, M. J., Hamid, M. M. A., Hwang, J., Karunajeewa, H., … Woyessa, A. (2024). Primaquine for uncomplicated Plasmodium vivax malaria in children younger than 15 years: a systematic review and individual patient data meta-analysis. The Lancet Child & Adolescent Health, 8(11), 798–808. https://doi.org/10.1016/s2352-4642(24)00210-4

Bennett, J. M., Narwal, S. K., Kabeche, S., Abegg, D., Thathy, V., Hackett, F., Yeo, T., Li, V. L., Muir, R., Faucher, F., Lovell, S., Blackman, M. J., Adibekian, A., Yeh, E., Fidock, D. A., & Bogyo, M. (2024). Mixed alkyl/aryl phosphonates identify metabolic serine hydrolases as antimalarial targets. Cell Chemical Biology, 31(9), 1714-1728.e10. https://doi.org/10.1016/j.chembiol.2024.07.006

Olisakwe, S. C., Thwing, J., Dionne, J. A., Irvin, R., Kachur, P. S., & Bruxvoort, K. J. (2024). Receipt of antimalarials among children aged 6–59 months in Nigeria from 2010 to 2021. Malaria Journal, 23(1). https://doi.org/10.1186/s12936-024-05075-x

Lawong, A., Gahalawat, S., Ray, S., Ho, N., Han, Y., Ward, K. E., Deng, X., Chen, Z., Kumar, A., Xing, C., Hosangadi, V., Fairhurst, K. J., Tashiro, K., Liszczak, G., Shackleford, D. M., Katneni, K., Chen, G., Saunders, J., Crighton, E., … Phillips, M. A. (2024). Identification of potent and reversible piperidine carboxamides that are species-selective orally active proteasome inhibitors to treat malaria. Cell Chemical Biology, 31(8), 1503-1517.e19. https://doi.org/10.1016/j.chembiol.2024.07.001

Collins, J. E., Jiang, T., Lee, J. W., Wendt, K., Nardella, F., Jeon, J., Paes, R., Santos, N. M., Rocamora, F., Chang, M., Schaefer, S., Cichewicz, R. H., Winzeler, E. A., & Chakrabarti, D. (2024). Understanding the Antiplasmodial Action of Resistance-Refractory Xanthoquinodin A1. ACS Infectious Diseases, 10(6), 2276–2287. https://doi.org/10.1021/acsinfecdis.4c00232

Small-Saunders, J. L., Sinha, A., Bloxham, T. S., Hagenah, L. M., Sun, G., Preiser, P. R., Dedon, P. C., & Fidock, D. A. (2024). tRNA modification reprogramming contributes to artemisinin resistance in Plasmodium falciparum. Nature Microbiology, 9(6), 1483–1498. https://doi.org/10.1038/s41564-024-01664-3

Nguyen, W., Boulet, C., Dans, M. G., Loi, K., Jarman, K. E., Watson, G. M., Tham, W.-H., Fairhurst, K. J., Yeo, T., Fidock, D. A., Wittlin, S., Chowdury, M., de Koning-Ward, T. F., Chen, G., Yan, D., Charman, S. A., Baud, D., Brand, S., Jackson, P. F., … Sleebs, B. E. (2024). Activity refinement of aryl amino acetamides that target the P. falciparum STAR-related lipid transfer 1 protein. European Journal of Medicinal Chemistry, 270, 116354. https://doi.org/10.1016/j.ejmech.2024.116354

Platon, L., Leroy, D., Fidock, D. A., & Ménard, D. (2024). Drug-induced stress mediates Plasmodium falciparum ring-stage growth arrest and reduces in vitro parasite susceptibility to artemisinin. Microbiology Spectrum, 12(4). https://doi.org/10.1128/spectrum.03500-23

Mok, S., & Fidock, D. A. (2024). Determinants of piperaquine-resistant malaria in South America. The Lancet Infectious Diseases, 24(2), 114–116. https://doi.org/10.1016/s1473-3099(23)00564-9

Xie, S. C., Wang, Y., Morton, C. J., Metcalfe, R. D., Dogovski, C., Pasaje, C. F. A., Dunn, E., Luth, M. R., Kumpornsin, K., Istvan, E. S., Park, J. S., Fairhurst, K. J., Ketprasit, N., Yeo, T., Yildirim, O., Bhebhe, M. N., Klug, D. M., Rutledge, P. J., Godoy, L. C., … Tilley, L. (2024). Reaction hijacking inhibition of Plasmodium falciparum asparagine tRNA synthetase. Nature Communications, 15(1). https://doi.org/10.1038/s41467-024-45224-z

Hagenah, L. M., Dhingra, S. K., Small-Saunders, J. L., Qahash, T., Willems, A., Schindler, K. A., Rangel, G. W., Gil-Iturbe, E., Kim, J., Akhundova, E., Yeo, T., Okombo, J., Mancia, F., Quick, M., Roepe, P. D., Llinás, M., & Fidock, D. A. (2024). Additional PfCRT mutations driven by selective pressure for improved fitness can result in the loss of piperaquine resistance and altered Plasmodium falciparum physiology. MBio, 15(1). https://doi.org/10.1128/mbio.01832-23

Wang, L., Bohmer, M. J., Wang, J., Nardella, F., Calla, J., Laureano De Souza, M., Schindler, K. A., Montejo, L., Mittal, N., Rocamora, F., Treat, M., Charlton, J. T., Tumwebaze, P. K., Rosenthal, P. J., Cooper, R. A., Chakrabarti, R., Winzeler, E. A., Chakrabarti, D., & Gray, N. S. (2024). Discovery of Potent Antimalarial Type II Kinase Inhibitors with Selectivity over Human Kinases. Journal of Medicinal Chemistry, 67(2), 1460–1480. https://doi.org/10.1021/acs.jmedchem.3c02046

Eisenberg, S.-L., & Krieger, A. E. (2023). A comprehensive approach to optimizing malaria prevention in pregnant women: evaluating the efficacy, cost-effectiveness, and resistance of IPTp-SP and IPTp-DP. Global Health Action, 16(1). https://doi.org/10.1080/16549716.2023.2231257

Mehdipour, P., Rajasekhar, M., Dini, S., Zaloumis, S., Abreha, T., Adam, I., Awab, G. R., Baird, J. K., Brasil, L. W., Chu, C. S., Cui, L., Daher, A., do Socorro M Gomes, M., Gonzalez‑Ceron, L., Hwang, J., Karunajeewa, H., Lacerda, M. V. G., Ladeia-Andrade, S., … Leslie, T. (2023). Effect of adherence to primaquine on the risk of Plasmodium vivax recurrence: a WorldWide Antimalarial Resistance Network systematic review and individual patient data meta-analysis. Malaria Journal, 22(1). https://doi.org/10.1186/s12936-023-04725-w

Kümpornsin, K., Kochakarn, T., Yeo, T., Okombo, J., Luth, M. R., Hoshizaki, J., Rawat, M., Pearson, R. D., Schindler, K. A., Mok, S., Park, H., Uhlemann, A.-C., Jana, G. P., Maity, B. C., Laleu, B., Chenu, E., Duffy, J., Moliner Cubel, S., Franco, V., … Lee, M. C. S. (2023). Generation of a mutator parasite to drive resistome discovery in Plasmodium falciparum. Nature Communications, 14(1). https://doi.org/10.1038/s41467-023-38774-1

Stadler, E., Maiga, M., Friedrich, L., Thathy, V., Demarta-Gatsi, C., Dara, A., Sogore, F., Striepen, J., Oeuvray, C., Djimdé, A. A., Lee, M. C. S., Dembélé, L., Fidock, D. A., Khoury, D. S., & Spangenberg, T. (2023). Propensity of selecting mutant parasites for the antimalarial drug cabamiquine. Nature Communications, 14(1). https://doi.org/10.1038/s41467-023-40974-8

Bopp, S., Pasaje, C. F. A., Summers, R. L., Magistrado-Coxen, P., Schindler, K. A., Corpas-Lopez, V., Yeo, T., Mok, S., Dey, S., Smick, S., Nasamu, A. S., Demas, A. R., Milne, R., Wiedemar, N., Corey, V., Gomez-Lorenzo, M. D. G., Franco, V., Early, A. M., Lukens, A. K., … Wirth, D. F. (2023). Potent acyl-CoA synthetase 10 inhibitors kill Plasmodium falciparum by disrupting triglyceride formation. Nature Communications, 14(1). https://doi.org/10.1038/s41467-023-36921-2

Siqueira-Neto, J. L., Wicht, K. J., Chibale, K., Burrows, J. N., Fidock, D. A., & Winzeler, E. A. (2023). Antimalarial drug discovery: progress and approaches. Nature Reviews Drug Discovery, 22(10), 807–826. https://doi.org/10.1038/s41573-023-00772-9

van der Plas, J. L., Kuiper, V. P., Bagchus, W. M., Bödding, M., Yalkinoglu, Ö., Tappert, A., Seitzinger, A., Spangenberg, T., Bezuidenhout, D., Wilkins, J., Oeuvray, C., Dhingra, S. K., Thathy, V., Fidock, D. A., Smidt, L. C. A., Roozen, G. V. T., Koopman, J. P. R., Lamers, O. A. C., Sijtsma, J., … Khandelwal, A. (2023). Causal chemoprophylactic activity of cabamiquine against Plasmodium falciparum in a controlled human malaria infection: a randomised, double-blind, placebo-controlled study in the Netherlands. The Lancet Infectious Diseases, 23(10), 1164–1174. https://doi.org/10.1016/s1473-3099(23)00212-8

Mihreteab, S., Platon, L., Berhane, A., Stokes, B. H., Warsame, M., Campagne, P., Criscuolo, A., Ma, L., Petiot, N., Doderer-Lang, C., Legrand, E., Ward, K. E., Zehaie Kassahun, A., Ringwald, P., Fidock, D. A., & Ménard, D. (2023). Increasing Prevalence of Artemisinin-Resistant HRP2-Negative Malaria in Eritrea. New England Journal of Medicine, 389(13), 1191–1202. https://doi.org/10.1056/nejmoa2210956

Rajasekhar, M., Simpson, J. A., Ley, B., Edler, P., Chu, C. S., Abreha, T., Awab, G. R., Baird, J. K., Bancone, G., Barber, B. E., Grigg, M. J., Hwang, J., Karunajeewa, H., Lacerda, M. V. G., Ladeia-Andrade, S., Llanos-Cuentas, A., Pukrittayakamee, S., Rijal, K. R., Saravu, K., … Woyessa, A. (2024). Primaquine dose and the risk of haemolysis in patients with uncomplicated Plasmodium vivax malaria: a systematic review and individual patient data meta-analysis. The Lancet Infectious Diseases, 24(2), 184–195. https://doi.org/10.1016/s1473-3099(23)00431-0

Commons, R. J., Rajasekhar, M., Edler, P., Abreha, T., Awab, G. R., Baird, J. K., Barber, B. E., Chu, C. S., Cui, L., Daher, A., Gonzalez-Ceron, L., Grigg, M. J., Hwang, J., Karunajeewa, H., Lacerda, M. V. G., Ladeia-Andrade, S., Lidia, K., Llanos-Cuentas, A., Longley, R. J., … Woyessa, A. (2024). Effect of primaquine dose on the risk of recurrence in patients with uncomplicated Plasmodium vivax: a systematic review and individual patient data meta-analysis. The Lancet Infectious Diseases, 24(2), 172–183. https://doi.org/10.1016/s1473-3099(23)00430-9

Armstrong, J. F., Campo, B., Alexander, S. P. H., Arendse, L. B., Cheng, X., Davenport, A. P., Faccenda, E., Fidock, D. A., Godinez‐Macias, K. P., Harding, S. D., Kato, N., Lee, M. C. S., Luth, M. R., Mazitschek, R., Mittal, N., Niles, J. C., Okombo, J., Ottilie, S., Pasaje, C. F. A., … Davies, J. A. (2023). Advances in malaria pharmacology and the online guide to MALARIA PHARMACOLOGY: IUPHAR review 38. British Journal of Pharmacology, 180(15), 1899–1929. Portico. https://doi.org/10.1111/bph.16144

Ward, K. E., Christensen, P., Racklyeft, A., Dhingra, S. K., Chua, A. C. Y., Remmert, C., Suwanarusk, R., Matheson, J., Blackman, M. J., Kaneko, O., Kyle, D. E., Lee, M. C. S., Moon, R. W., Snounou, G., Rénia, L., Fidock, D. A., Russell, B., & Bifani, P. (2022). Integrative Genetic Manipulation of Plasmodium cynomolgi Reveals Multidrug Resistance-1 Y976F Associated With Increased In Vitro Susceptibility to Mefloquine. The Journal of Infectious Diseases, 227(10), 1121–1126. https://doi.org/10.1093/infdis/jiac469

Deni, I., Stokes, B. H., Ward, K. E., Fairhurst, K. J., Pasaje, C. F. A., Yeo, T., Akbar, S., Park, H., Muir, R., Bick, D. S., Zhan, W., Zhang, H., Liu, Y. J., Ng, C. L., Kirkman, L. A., Almaliti, J., Gould, A. E., Duffey, M., O’Donoghue, A. J., … Fidock, D. A. (2023). Mitigating the risk of antimalarial resistance via covalent dual-subunit inhibition of the Plasmodium proteasome. Cell Chemical Biology, 30(5), 470-485.e6. https://doi.org/10.1016/j.chembiol.2023.03.002

Ashton, T. D., Dans, M. G., Favuzza, P., Ngo, A., Lehane, A. M., Zhang, X., Qiu, D., Chandra Maity, B., De, N., Schindler, K. A., Yeo, T., Park, H., Uhlemann, A.-C., Churchyard, A., Baum, J., Fidock, D. A., Jarman, K. E., Lowes, K. N., Baud, D., … Sleebs, B. E. (2023). Optimization of 2,3-Dihydroquinazolinone-3-carboxamides as Antimalarials Targeting PfATP4. Journal of Medicinal Chemistry, 66(5), 3540–3565. https://doi.org/10.1021/acs.jmedchem.2c02092

Istvan, E. S., Guerra, F., Abraham, M., Huang, K.-S., Rocamora, F., Zhao, H., Xu, L., Pasaje, C., Kumpornsin, K., Luth, M. R., Cui, H., Yang, T., Palomo Diaz, S., Gomez-Lorenzo, M. G., Qahash, T., Mittal, N., Ottilie, S., Niles, J., Lee, M. C. S., … Winzeler, E. A. (2023). Cytoplasmic isoleucyl tRNA synthetase as an attractive multistage antimalarial drug target. Science Translational Medicine, 15(686). https://doi.org/10.1126/scitranslmed.adc9249

Kucharski, M., Wirjanata, G., Nayak, S., Boentoro, J., Dziekan, J. M., Assisi, C., van der Pluijm, R. W., Miotto, O., Mok, S., Dondorp, A. M., & Bozdech, Z. (2023). Short tandem repeat polymorphism in the promoter region of cyclophilin 19B drives its transcriptional upregulation and contributes to drug resistance in the malaria parasite Plasmodium falciparum. PLOS Pathogens, 19(1), e1011118. https://doi.org/10.1371/journal.ppat.1011118

Wicht, K. J., Small-Saunders, J. L., Hagenah, L. M., Mok, S., & Fidock, D. A. (2022). Mutant PfCRT Can Mediate Piperaquine Resistance in African Plasmodium falciparum With Reduced Fitness and Increased Susceptibility to Other Antimalarials. The Journal of Infectious Diseases, 226(11), 2021–2029. https://doi.org/10.1093/infdis/jiac365

de Vries, L. E., Jansen, P. A. M., Barcelo, C., Munro, J., Verhoef, J. M. J., Pasaje, C. F. A., Rubiano, K., Striepen, J., Abla, N., Berning, L., Bolscher, J. M., Demarta-Gatsi, C., Henderson, R. W. M., Huijs, T., Koolen, K. M. J., Tumwebaze, P. K., Yeo, T., Aguiar, A. C. C., Angulo-Barturen, I., … Dechering, K. J. (2022). Preclinical characterization and target validation of the antimalarial pantothenamide MMV693183. Nature Communications, 13(1). https://doi.org/10.1038/s41467-022-29688-5

Laleu, B., Rubiano, K., Yeo, T., Hallyburton, I., Anderson, M., Crespo‐Fernandez, B., Gamo, F., Antonova‐Koch, Y., Orjuela‐Sanchez, P., Wittlin, S., Jana, G. P., Maity, B. C., Chenu, E., Duffy, J., Sjö, P., Waterson, D., Winzeler, E., Guantai, E., Fidock, D. A., & Hansson, T. G. (2022). Exploring a Tetrahydroquinoline Antimalarial Hit from the Medicines for Malaria Pathogen Box and Identification of its Mode of Resistance as PfeEF2. ChemMedChem, 17(22). Portico. https://doi.org/10.1002/cmdc.202200393

Ugarte-Gil, M. F., Hanly, J., Urowitz, M., Gordon, C., Bae, S.-C., Romero-Diaz, J., Sanchez-Guerrero, J., Bernatsky, S., Clarke, A. E., Wallace, D. J., Isenberg, D. A., Rahman, A., Merrill, J. T., Fortin, P. R., Gladman, D. D., Bruce, I. N., Petri, M., Ginzler, E. M., Dooley, M. A., … Alarcón, G. S. (2022). Remission and low disease activity (LDA) prevent damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort. Annals of the Rheumatic Diseases, 81(11), 1541–1548. https://doi.org/10.1136/ard-2022-222487

Okombo, J., Mok, S., Qahash, T., Yeo, T., Bath, J., Orchard, L. M., Owens, E., Koo, I., Albert, I., Llinás, M., & Fidock, D. A. (2022). Piperaquine-resistant PfCRT mutations differentially impact drug transport, hemoglobin catabolism and parasite physiology in Plasmodium falciparum asexual blood stages. PLOS Pathogens, 18(10), e1010926. https://doi.org/10.1371/journal.ppat.1010926

Arendse, L. B., Murithi, J. M., Qahash, T., Pasaje, C. F. A., Godoy, L. C., Dey, S., Gibhard, L., Ghidelli-Disse, S., Drewes, G., Bantscheff, M., Lafuente-Monasterio, M. J., Fienberg, S., Wambua, L., Gachuhi, S., Coertzen, D., van der Watt, M., Reader, J., Aswat, A. S., Erlank, E., … Chibale, K. (2022). The anticancer human mTOR inhibitor sapanisertib potently inhibits multiple Plasmodium kinases and life cycle stages. Science Translational Medicine, 14(667). https://doi.org/10.1126/scitranslmed.abo7219

Lowe, M. A., Cardenas, A., Valentin, J.-P., Zhu, Z., Abendroth, J., Castro, J. L., Class, R., Delaunois, A., Fleurance, R., Gerets, H., Gryshkova, V., King, L., Lorimer, D. D., MacCoss, M., Rowley, J. H., Rosseels, M.-L., Royer, L., Taylor, R. D., Wong, M., … de Haro, T. (2022). Discovery and Characterization of Potent, Efficacious, Orally Available Antimalarial Plasmepsin X Inhibitors and Preclinical Safety Assessment of UCB7362. Journal of Medicinal Chemistry, 65(20), 14121–14143. https://doi.org/10.1021/acs.jmedchem.2c01336

Ward, K. E., Fidock, D. A., & Bridgford, J. L. (2022). Plasmodium falciparum resistance to artemisinin-based combination therapies. Current Opinion in Microbiology, 69, 102193. https://doi.org/10.1016/j.mib.2022.102193

Qiu, D., Pei, J. V., Rosling, J. E. O., Thathy, V., Li, D., Xue, Y., Tanner, J. D., Penington, J. S., Aw, Y. T. V., Aw, J. Y. H., Xu, G., Tripathi, A. K., Gnadig, N. F., Yeo, T., Fairhurst, K. J., Stokes, B. H., Murithi, J. M., Kümpornsin, K., Hasemer, H., … Lehane, A. M. (2022). A G358S mutation in the Plasmodium falciparum Na+ pump PfATP4 confers clinically-relevant resistance to cipargamin. Nature Communications, 13(1). https://doi.org/10.1038/s41467-022-33403-9

Barber, B. E., Fernandez, M., Patel, H. B., Barcelo, C., Woolley, S. D., Patel, H., Llewellyn, S., Abd-Rahman, A. N., Sharma, S., Jain, M., Ghoghari, A., Di Resta, I., Fuchs, A., Deni, I., Yeo, T., Mok, S., Fidock, D. A., Chalon, S., Möhrle, J. J., … Kansagra, K. (2022). Safety, pharmacokinetics, and antimalarial activity of the novel triaminopyrimidine ZY-19489: a first-in-human, randomised, placebo-controlled, double-blind, single ascending dose study, pilot food-effect study, and volunteer infection study. The Lancet Infectious Diseases, 22(6), 879–890. https://doi.org/10.1016/s1473-3099(21)00679-4

Fidock, D. A., & Rosenthal, P. J. (2021). Artemisinin resistance in Africa: How urgent is the threat? Med, 2(12), 1287–1288. https://doi.org/10.1016/j.medj.2021.11.005